$22.24
-0.29[-1.29%]
At close: May 8
$22.24
0[0.00%]
After Hours: 4:00PM EDT
Beam Therapeutics
(NASDAQ:BEAM)Latest News for Beam Therapeutics Stock (NASDAQ:BEAM)
Beam Therapeutics Stock (NASDAQ: BEAM)
Categories: All
Wednesday, May 08, 2024
Tuesday, May 07, 2024
- Beam Therapeutics Ended Q1 2024 With $1.1B In Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans Into 2027Benzinga Newsdesk - 1 day ago
- Beam Therapeutics Q1 2024 GAAP EPS $(1.21) Beats $(1.44) Estimate, Sales $7.410M Miss $16.967M EstimateBenzinga Newsdesk - 1 day ago
Tuesday, April 23, 2024
Friday, April 12, 2024
Tuesday, April 02, 2024
- Beam Therapeutics shares are trading lower after Verve Therapeutics paused enrollment in its Heart-1 clinical trial. Verve and Beam previously entered a license agreement for access to Beam's base editing, gene editing, and delivery technologies.Benzinga Newsdesk - Apr 2, 2024, 3:30PM
- Gene Therapy Side Effects: Verve Therapeutics Halts Enrollment Of Lead Gene Therapy Trial In Patients With Bad CholesterolVandana Singh - Apr 2, 2024, 12:19PM
Wednesday, March 27, 2024
Tuesday, March 26, 2024
Wednesday, February 28, 2024
Tuesday, February 27, 2024
- Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionAvi Kapoor - Feb 27, 2024, 1:18PM
- Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On TuesdayAvi Kapoor - Feb 27, 2024, 10:27AM
- Beam Therapeutics shares are trading higher after the company reported Q4 financial results.Benzinga Newsdesk - Feb 27, 2024, 9:21AM
- Recap: Beam Therapeutics Q4 EarningsBenzinga Insights - Feb 27, 2024, 8:25AM
- Beam Therapeutics Q4 EPS $1.73 Vs $(0.54) YoY, Sales $316.19M Beat $18.67M Estimate, Cash Runway of $1.2B Expected to Support Operating Plans into 2027Benzinga Newsdesk - Feb 27, 2024, 6:34AM
Friday, February 09, 2024
Monday, January 29, 2024
Tuesday, January 16, 2024
Monday, January 08, 2024
Friday, December 15, 2023
Friday, December 08, 2023
- Beam Therapeutics shares are trading lower after Jefferies downgraded the stock from Buy to Hold and lowered its price target from $75 to $30.Benzinga Newsdesk - Dec 8, 2023, 12:49PM
- Lululemon To Rally Around 14%? Here Are 10 Top Analyst Forecasts For FridayAvi Kapoor - Dec 8, 2023, 7:20AM
- Jefferies Downgrades Beam Therapeutics to Hold, Lowers Price Target to $30Benzinga Newsdesk - Dec 8, 2023, 6:56AM
Wednesday, November 29, 2023
Friday, November 17, 2023
Monday, November 13, 2023
Wednesday, November 08, 2023
- Beam Therapeutics: Q3 Earnings InsightsBenzinga Insights - Nov 8, 2023, 6:40AM
- Beam Therapeutics Expects That Its Cash, Cash Equivalents And Marketable Securities Of $1B And Upfront Proceeds From Lilly, Is To Fund Its Anticipated Operating Expenses And Capital Expenditure Requirements Into 2H Of 2026Benzinga Newsdesk - Nov 8, 2023, 6:33AM
- Beam Therapeutics Q3 EPS $(1.22) Beats $(1.34) Estimate, Sales $17.19M Miss $17.49M EstimateBenzinga Newsdesk - Nov 8, 2023, 6:31AM
Tuesday, October 31, 2023
- Why JetBlue Airways Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionLisa Levin - Oct 31, 2023, 1:36PM
- Arista Networks, JinkoSolar, Repligen, Shutterstock And Other Big Stocks Moving Higher On TuesdayLisa Levin - Oct 31, 2023, 12:04PM
- Why Beam Therapeutics Stock Is Getting Bought TodayAdam Eckert - Oct 31, 2023, 8:52AM
- Beam Therapeutics shares are trading higher after Eli Lilly agreed to acquire certain rights under Beam's agreement with Verve Therapeutics.Benzinga Newsdesk - Oct 31, 2023, 8:52AM
- Beam Enters Agreement For Lilly To Acquire Beam's Opt-In Rights To Verve Therapeutics' Base Editing Programs For Cardiovascular Disease; Total Of Up To $600M In Potential Total Deal ConsiderationBenzinga Newsdesk - Oct 31, 2023, 6:02AM
Monday, October 30, 2023
Wednesday, October 25, 2023
- Beam Therapeutics President and CSO Acquires 90,900 Shares After Exercising Company Stock OptionsBenzinga Insights - Oct 25, 2023, 11:00AM
- Beam Therapeutics Presents Preclinical Data Highlighting Utility And Durability of BEAM-301 To Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation At ESGCTBenzinga Newsdesk - Oct 25, 2023, 6:33AM
Monday, October 23, 2023
Thursday, October 19, 2023
- Why Nokia Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionLisa Levin - Oct 19, 2023, 1:52PM
- What's Going On With Beam Therapeutics Stock Thursday?Adam Eckert - Oct 19, 2023, 10:50AM
- Beam Therapeutics shares are trading lower after the company announced portfolio prioritization and strategic restructuring.Benzinga Newsdesk - Oct 19, 2023, 10:37AM
- Beam Therapeutics Announces Portfolio Prioritization And Strategic Restructuring Focused On Potential Near-Term Value Drivers And Long-Term Growth Of Precision Genetic Medicines PipelineBenzinga Newsdesk - Oct 19, 2023, 8:47AM